Formulation and development of novel control release transdermal patches of carvedilol to improve bioavailability for the treatment of heart failure

Adebayo, 2017, Heart failure: Definition, classification, and pathophysiology–A mini-review, Nigerian Journal of Cardiology, 14, 9, 10.4103/0189-7969.201913 Alexander, 2012, Approaches for breaking the barriers of drug permeation through transdermal drug delivery, Journal of Controlled Release, 164, 26, 10.1016/j.jconrel.2012.09.017 Alkilani, 2015, Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum, Pharmaceutics, 7, 438, 10.3390/pharmaceutics7040438 Allam, 2011, Bioavailability: A review, International Journal of Novel Drug delivery technology, 1, 77 Aparna, 2013, Formulation and in vitro evaluation of carvedilol transdermal delivery system, Tropical Journal of Pharmaceutical Research, 12, 461 Fröhlich, 2015, Carvedilol compared with metoprolol succinate in the treatment and prognosis of patients with stable chronic heart failure: carvedilol or metoprolol evaluation study, Circulation Heart Failure, 8, 887, 10.1161/CIRCHEARTFAILURE.114.001701 Gannu, 2007, Development of nitrendipine transdermal patches: in vitro and ex vivo characterization, Current Drug Delivery, 4, 69, 10.2174/156720107779314767 Inamdar, 2016, Heart failure: diagnosis, management and utilization, Journal of clinical medicine, 5, 62, 10.3390/jcm5070062 Kapoor, 2018, Chemical penetration enhancers for transdermal drug delivery system, Journal of Drug Delivery and Therapeutics, 8, 62, 10.22270/jddt.v8i5-s.1952 Katz, 2018, Pathophysiology of chronic systolic heart failure. A view from the periphery, Annals of the American Thoracic Society, 15, S38, 10.1513/AnnalsATS.201710-789KV Kveiborg, 2007, Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial, Vascular health and risk management, 3, 31 Lonn, 2000, Drug treatment in heart failure, Bmj, 320, 1188, 10.1136/bmj.320.7243.1188 Mounika, 2014, Formulation and evaluation of carvedilol transdermal patches with hydrophilic polymers, World Journal of Pharmaceutical Research, 3, 815 Oza, 2013, formulation and evaluation of carvedilol transdermal patches by using Hydrophilic and hydrophobic polymers, International Journal for Pharmaceutical Research Scholars, 2, 151 Patra, 2017, Pharmaceutical significance of Eudragit: A review, Future Journal of Pharmaceutical Sciences, 3, 33, 10.1016/j.fjps.2017.02.001 Rastogi, 2014, Transdermal drug delivery system: An overview, Asian Journal of Pharmaceutics, 6, 161, 10.4103/0973-8398.104828 Roger, 2013, Epidemiology of heart failure, Circulation research, 113, 646, 10.1161/CIRCRESAHA.113.300268 Tanwar, 2007, Development and evaluation of carvedilol transdermal patches, Acta pharmaceutica, 57, 151, 10.2478/v10007-007-0012-x Ubaidulla, 2007, ransdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics, Aaps Pharmscitech, 8, E13, 10.1208/pt0801002 Vahdati, 2013, Solubility of carvedilol in ethanol+ propylene glycol mixtures at various temperatures, Industrial & Engineering Chemistry Research, 52, 16630, 10.1021/ie403054z Zsikó, 2019, Methods to evaluate skin penetration in vitro, Scientia Pharmaceutica, 87, 19, 10.3390/scipharm87030019